# Retlirafusp alfa

Source: https://onco.cc/drugs/retlirafusp-alfa/  
OnCo record `retlirafusp-alfa` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.

## Summary

SHR-1701 combines PD-L1 blockade with a TGF-beta trap in a single molecule. Hengrui and Suncadia are running phase 3 trials with capecitabine and oxaliplatin (CAPOX) in first-line advanced gastric and gastro-oesophageal junction cancer, and further studies in cervical and other cancers, after Merck KGaA's bintrafusp alfa was discontinued in 2023 when its lung and biliary trials failed.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: SHR-1701
- Modality: Bifunctional fusion protein (anti-PD-L1 antibody fused to a TGF-beta receptor II trap), intravenous
- Mechanism: One arm blocks PD-L1 while the fused receptor domain soaks up TGF-beta in the tumour, attacking two immunosuppressive signals at once; the class was pioneered by bintrafusp alfa.

## Sources

- ClinicalTrials.gov: trials of Retlirafusp alfa: https://clinicaltrials.gov/search?intr=SHR-1701

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- trials: [A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer](https://onco.cc/trials/nct04950322/), [Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer](https://onco.cc/trials/nct05671822/), [Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects](https://onco.cc/trials/nct07175220/), [Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct07102901/), [SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05300269/)

---
JSON: https://onco.cc/api/v1/entities/retlirafusp-alfa.json